| Detected | Trial | Change |
|---|---|---|
| 2026-06-11 | NCT06235801 A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-06-09 | NCT06824103 Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With… |
date change Primary completion moved earlier: 2029-11-29 -> 2029-05-10 |
| 2026-06-09 | NCT03681561 Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma |
date change Primary completion pushed: 2026-03 -> 2026-09 |
| 2026-06-06 | NCT06150157 A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated… |
date change Completion pushed: 2028-04-12 -> 2028-05-12 |
| 2026-06-05 | NCT03514069 Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma |
Trial completed |
| 2026-06-05 | NCT03514069 Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma |
date change Completion moved earlier: 2026-05-31 -> 2021-09-29 |
| 2026-06-05 | NCT07252050 Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease |
Sponsor changed: University of Colorado, Denver -> Arkansas Children's Hospital Research Institute |
| 2026-06-04 | NCT07406932 A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as… |
Recruitment opened |
| 2026-06-03 | NCT06847867 A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome |
Primary endpoint(s) modified |
| 2026-06-03 | NCT07357727 A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) |
Trial sites expanded: 6 -> 9 locations |
| 2026-06-02 | NCT05998408 JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-06-02 | NCT05998408 JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure |
Enrollment reduced: 145 -> 13 participants |
| 2026-06-02 | NCT07569081 A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles… |
Enrollment reduced: 192 -> 136 participants |
| 2026-05-29 | NCT03017820 A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of… |
Enrollment reduced: 127 -> 99 participants |
| 2026-05-28 | NCT07464951 CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia |
Recruitment opened |
| 2026-05-23 | NCT06388564 A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-05-23 | NCT06752694 Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-05-23 | NCT06752694 Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell… |
Enrollment reduced: 20 -> 1 participants |
| 2026-05-23 | NCT06752694 Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell… |
date change Primary completion moved earlier: 2027-12-31 -> 2026-01-23 |
| 2026-05-23 | NCT06752694 Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell… |
date change Completion moved earlier: 2027-12-31 -> 2026-10-15 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-11 | NCT07643025 Belumosudil With Ruxolitnib as Second Line Therapy for Chronic Graft Versus Host Disease… | Phase 2 | Not Yet Recruiting |
| 2026-05-15 | NCT07588945 daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCT | Phase 3 | Not Yet Recruiting |
| 2026-05-14 | NCT07588139 A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of… | Phase 1 | Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT06824103 | Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With… | Graft vs. Host Disease | Recruiting |
| NCT07498205 | Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low… | Myelofibrosis | Not Yet Recruiting |
| NCT02386800 | CINC424A2X01B Rollover Protocol | Primary Myelofibrosis | Active, Not Recruiting |
| NCT07352566 | Utilization of a Microdevice for Psoriasis and Atopic Dermatitis | Psoriasis | Not Yet Recruiting |
| Phase 3 | |||
| NCT07317700 | A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis | MF | Recruiting |
| NCT06351631 | A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) | Thrombocythemia, Essential | Recruiting |
| NCT04116502 | MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in… | Polycythemia Vera | Recruiting |
| NCT06615050 | A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant… | Graft-versus-host Disease (GVHD) | Recruiting |
| NCT06079879 | A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in… | Essential Thrombocythemia | Recruiting |
| NCT06456346 | Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) | Essential Thrombocythemia | Recruiting |
| NCT07357727 | A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) | Primary Myelofibrosis (PMF) | Recruiting |
| NCT04468984 | Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best… | Myelofibrosis (MF) | Active, Not Recruiting |
| NCT04562389 | Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis | Myelofibrosis | Active, Not Recruiting |
| NCT07588945 | daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCT | Transplant-Related Disorder | Not Yet Recruiting |
| Phase 2/3 | |||
| NCT07366801 | Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell… | Acute Myeloid Leukemia, Relapsed | Recruiting |
| NCT07569081 | A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles… | VEXAS Syndrome | Not Yet Recruiting |
| Phase 2 | |||
| NCT06991101 | Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for… | Glioblastoma | Recruiting |
| NCT04644211 | Ruxolitinib in Thrombocythemia and Polycythemia Vera | Essential Thrombocythemia | Recruiting |
| NCT04370301 | Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or… | Primary Myelofibrosis | Recruiting |
| NCT07340723 | Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease ) | GVHD,Acute | Recruiting |
| NCT05037760 | A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis | Myelofibrosis | Recruiting |
| NCT05592015 | Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia | T-Cell Large Granular Lymphocyte Leukemia | Recruiting |
| NCT05980806 | A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and… | Myelofibrosis | Recruiting |
| NCT07228624 | Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With… | Myelodysplastic/Myeloproliferative Neoplasm | Recruiting |
| NCT06345495 | High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients… | Splenomegaly | Recruiting |